{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:40:59Z","timestamp":1792197659484,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01037-4","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:56:52Z","timestamp":1792195012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brexpiprazole for Individual Agitation Symptoms in Alzheimer\u2019s Dementia: A Caregiver-Centered Post Hoc Analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-1738","authenticated-orcid":false,"given":"Anton P.","family":"Porsteinsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5882-0920","authenticated-orcid":false,"given":"Sanjeda R.","family":"Chumki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-4701","authenticated-orcid":false,"given":"Anton M.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-5663","authenticated-orcid":false,"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1905-1142","authenticated-orcid":false,"given":"Pedro","family":"Such","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5975-9810","authenticated-orcid":false,"given":"C. Brendan","family":"Montano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"1","key":"1037_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000543578","volume":"60","author":"R Wang","year":"1990","unstructured":"Wang R. Global burden of Alzheimer\u2019s disease and other dementias during 1990\u20132021: a Global Burden of Disease and Risk Factors Study 2021-based study. Neuroepidemiology. 1990;60(1):16\u201327.","journal-title":"Neuroepidemiology"},{"issue":"3","key":"1037_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/gps.5030","volume":"34","author":"R Halpern","year":"2019","unstructured":"Halpern R, Seare J, Tong J, Hartry A, Olaoye A, Aigbogun MS. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease\/dementia. Int J Geriatr Psychiatry. 2019;34(3):420\u201331.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"1037_CR3","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/gps.5604","volume":"36","author":"H Fillit","year":"2021","unstructured":"Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, et al. Impact of agitation in long-term care residents with dementia in the United States. Int J Geriatr Psychiatry. 2021;36(12):1959\u201369.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"1037_CR4","doi-asserted-by":"publisher","first-page":"M77","DOI":"10.1093\/geronj\/44.3.M77","volume":"44","author":"J Cohen-Mansfield","year":"1989","unstructured":"Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):M77-84.","journal-title":"J Gerontol"},{"key":"1037_CR5","volume-title":"Instruction manual for the Cohen-Mansfield Agitation Inventory (CMAI)","author":"J Cohen-Mansfield","year":"1991","unstructured":"Cohen-Mansfield J. Instruction manual for the Cohen-Mansfield Agitation Inventory (CMAI). Rockville, MD: The Research Institute of the Hebrew Home of Greater Washington; 1991."},{"issue":"4","key":"1037_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1017\/S1041610222001041","volume":"36","author":"M Sano","year":"2024","unstructured":"Sano M, Cummings J, Auer S, et al. Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition. Int Psychogeriatr. 2024;36(4):238\u201350.","journal-title":"Int Psychogeriatr"},{"key":"1037_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.trci.2019.10.004","volume":"5","author":"M Cloutier","year":"2019","unstructured":"Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, et al. Institutionalization risk and costs associated with agitation in Alzheimer\u2019s disease. Alzheimers Dement Transl Res Clin Interv. 2019;5:851\u201361.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"11","key":"1037_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013591","volume":"6","author":"M Knapp","year":"2016","unstructured":"Knapp M, Chua KC, Broadbent M, et al. Predictors of care home and hospital admissions and their costs for older people with Alzheimer\u2019s disease: findings from a large London case register. BMJ Open. 2016;6(11):e013591.","journal-title":"BMJ Open"},{"issue":"4","key":"1037_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1192\/bjpo.bp.117.005181","volume":"3","author":"G Livingston","year":"2017","unstructured":"Livingston G, Barber J, Marston L, et al. Prevalence of and associations with agitation in residents with dementia living in care homes: MARQUE cross-sectional study. BJPsych Open. 2017;3(4):171\u20138.","journal-title":"BJPsych Open"},{"issue":"2","key":"1037_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1532-5415.2009.02680.x","volume":"58","author":"T Okura","year":"2010","unstructured":"Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the Aging, Demographics, and Memory Study. J Am Geriatr Soc. 2010;58(2):330\u20137.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"1037_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","volume":"172","author":"ME Peters","year":"2015","unstructured":"Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172(5):460\u20135.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1037_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.36469\/jheor.2024.124455","volume":"11","author":"C Teigland","year":"2024","unstructured":"Teigland C, Pulungan Z, Bruhn D, Hwang S. Healthcare resource utilization among patients with agitation in Alzheimer dementia. J Health Econ Outcomes Res. 2024;11(2):118\u201324.","journal-title":"J Health Econ Outcomes Res."},{"issue":"3","key":"1037_CR13","first-page":"256","volume":"17","author":"ET \u00d6zel-Kizil","year":"2014","unstructured":"\u00d6zel-Kizil ET, Altinta\u015f HO, Ba\u015ftu\u011f G, Durmaz N, Altun\u00f6z U. The effect of agitation on caregivers\u2019 burden in patients with dementia. Turk J Geriatr. 2014;17(3):256\u201361.","journal-title":"Turk J Geriatr."},{"issue":"9","key":"1037_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11920-017-0818-2","volume":"19","author":"ST Cheng","year":"2017","unstructured":"Cheng ST. Dementia caregiver burden: a research update and critical analysis. Curr Psychiatry Rep. 2017;19(9):64.","journal-title":"Curr Psychiatry Rep."},{"issue":"1","key":"1037_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1186\/s12877-023-04234-0","volume":"23","author":"V Garc\u00eda-Mart\u00edn","year":"2023","unstructured":"Garc\u00eda-Mart\u00edn V, de Hoyos-Alonso MC, Delgado-Puebla R, Ariza-Cardiel G, Del Cura-Gonz\u00e1lez I. Burden in caregivers of primary care patients with dementia: influence of neuropsychiatric symptoms according to disease stage (NeDEM project). BMC Geriatr. 2023;23(1):525.","journal-title":"BMC Geriatr"},{"issue":"1","key":"1037_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1590\/1980-57642021dn15-010014","volume":"15","author":"LL Delfino","year":"2021","unstructured":"Delfino LL, Komatsu RS, Komatsu C, Neri AL, Cachioni M. Neuropsychiatric symptoms associated with family caregiver burden and depression. Dement Neuropsychol. 2021;15(1):128\u201335.","journal-title":"Dement Neuropsychol"},{"issue":"2","key":"1037_CR17","first-page":"421","volume":"25","author":"GT Grossberg","year":"2026","unstructured":"Grossberg GT, Willey C, Houle C, et al. Agitation in individuals with Alzheimer\u2019s disease: an assessment of behaviors using the Cohen-Mansfield Agitation Inventory in community-dwellers and impact on caregiver experience. Dement Geriatr Cogn Disord. 2026;25(2):421\u201342.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"1037_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/(SICI)1099-1166(199909)14:9<701::AID-GPS5>3.0.CO;2-#","volume":"14","author":"MT Gonzalez-Salvador","year":"1999","unstructured":"Gonzalez-Salvador MT, Arango C, Lyketsos CG, Barba AC. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry. 1999;14(9):701\u201310.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"4","key":"1037_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/gps.4014","volume":"29","author":"SA Zwijsen","year":"2014","unstructured":"Zwijsen SA, Kabboord A, Eefsting JA, et al. Nurses in distress? An explorative study into the relation between distress and individual neuropsychiatric symptoms of people with dementia in nursing homes. Int J Geriatr Psychiatry. 2014;29(4):384\u201391.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"1037_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jpsychires.2008.02.003","volume":"43","author":"J Cohen-Mansfield","year":"2008","unstructured":"Cohen-Mansfield J. Agitated behavior in persons with dementia: the relationship between type of behavior, its frequency, and its disruptiveness. J Psychiatr Res. 2008;43(1):64\u20139.","journal-title":"J Psychiatr Res"},{"issue":"5","key":"1037_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/psyg.12871","volume":"22","author":"KS Patrick","year":"2022","unstructured":"Patrick KS, Gunstad J, Martin JT, Chapman KR, Drost J, Spitznagel MB. Specific agitation behaviours in dementia differentially contribute to aspects of caregiver burden. Psychogeriatrics. 2022;22(5):688\u201398.","journal-title":"Psychogeriatrics"},{"key":"1037_CR22","unstructured":"Otsuka Pharmaceutical Co. Ltd. Rexulti\u00ae (brexpiprazole) tablets, for oral use. Prescribing information [United States]. 2026. Available from: https:\/\/www.otsuka-us.com\/media\/static\/Rexulti-PI.pdf. [June 17, 2026]."},{"key":"1037_CR23","unstructured":"Otsuka Pharmaceutical Co. Ltd. Rexulti\u00ae brexpiprazole tablets. Product monograph [Canada]. 2024. Available from: https:\/\/rexultimonograph.ca\/. [June 25, 2026]."},{"issue":"5","key":"1037_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1017\/S1092852924000427","volume":"29","author":"JL Cummings","year":"2024","unstructured":"Cummings JL, Brubaker M, Selzler KJ, Gonzalez ST, Patel M, Stahl SM. An overview of the pathophysiology of agitation in Alzheimer\u2019s dementia with a focus on neurotransmitters and circuits. CNS Spectr. 2024;29(5):316\u201325.","journal-title":"CNS Spectr."},{"issue":"3","key":"1037_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin\u2013dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589\u2013604.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1037_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","volume":"28","author":"GT Grossberg","year":"2020","unstructured":"Grossberg GT, Kohegyi E, Mergel V, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020;28(4):383\u2013400.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"1037_CR27","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","volume":"80","author":"D Lee","year":"2023","unstructured":"Lee D, Slomkowski M, Hefting N, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80(12):1307\u201316.","journal-title":"JAMA Neurol."},{"issue":"8","key":"1037_CR28","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/03007995.2025.2552278","volume":"41","author":"J Stroud","year":"2025","unstructured":"Stroud J, Cummings JL, Chumki SR, et al. Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer\u2019s disease. Curr Med Res Opin. 2025;41(8):1523\u201334.","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"1037_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40261-025-01517-9","volume":"46","author":"JL Cummings","year":"2026","unstructured":"Cummings JL, Chumki SR, Chang D, et al. Efficacy of brexpiprazole in participants with agitation associated with dementia due to Alzheimer\u2019s disease: pooled analysis of randomized controlled trials. Clin Drug Investig. 2026;46(3):281\u201392.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1037_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3233\/JAD-240491","volume":"102","author":"S Behl","year":"2024","unstructured":"Behl S, Slomkowski M, Chen D, et al. Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer\u2019s disease: a 12-week, active-treatment, extension trial. J Alzheimers Dis. 2024;102(2):520\u20139.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"1037_CR31","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939\u201344.","journal-title":"Neurology."},{"key":"1037_CR32","doi-asserted-by":"crossref","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"1037_CR33","volume-title":"Neuropsychiatric Inventory Nursing Home version (NPI-NH): comprehensive assessment of psychopathology in patients with dementia residing in nursing homes","author":"JL Cummings","year":"2009","unstructured":"Cummings JL. Neuropsychiatric Inventory Nursing Home version (NPI-NH): comprehensive assessment of psychopathology in patients with dementia residing in nursing homes. Los Angeles: David Geffen School of Medicine at UCLA; 2009."},{"issue":"12","key":"1037_CR34","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308\u201314.","journal-title":"Neurology."},{"issue":"11","key":"1037_CR35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/00019442-200511000-00010","volume":"13","author":"J Rabinowitz","year":"2005","unstructured":"Rabinowitz J, Davidson M, De Deyn PP, Katz I, Brodaty H, Cohen-Mansfield J. Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry. 2005;13(11):991\u20138.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"1037_CR36","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40263-025-01200-9","volume":"39","author":"A Shah","year":"2025","unstructured":"Shah A, Estilo A, Sheridan PL, et al. Safety and tolerability of brexpiprazole in participants with agitation associated with dementia due to Alzheimer\u2019s disease: pooled analysis of three randomized trials and an extension trial. CNS Drugs. 2025;39(10):1011\u201323.","journal-title":"CNS Drugs"},{"key":"1037_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/00325481.2025.2517535","volume":"137","author":"GT Grossberg","year":"2025","unstructured":"Grossberg GT, Sanford A, Montano CB, et al. A US-based practitioner\u2019s guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer\u2019s dementia \u2013 recommendations of an expert, multispecialty advisory panel. Postgrad Med. 2025;137:469\u201385.","journal-title":"Postgrad Med"},{"key":"1037_CR38","doi-asserted-by":"publisher","first-page":"1328874","DOI":"10.3389\/frdem.2024.1328874","volume":"3","author":"D Oberdhan","year":"2024","unstructured":"Oberdhan D, Palsgrove A, Houle C, et al. Care partner evaluation of the behaviors in the Cohen-Mansfield Agitation Inventory. Front Dement. 2024;3:1328874.","journal-title":"Front Dement."},{"issue":"2","key":"1037_CR39","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/nuf.12555","volume":"56","author":"FE Nunez","year":"2021","unstructured":"Nunez FE. Factors influencing decisions to admit family members with dementia to long-term care facilities. Nurs Forum. 2021;56(2):372\u201381.","journal-title":"Nurs Forum"},{"issue":"6","key":"1037_CR40","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1017\/S1041610213000057","volume":"25","author":"L Sury","year":"2013","unstructured":"Sury L, Burns K, Brodaty H. Moving in: adjustment of people living with dementia going into a nursing home and their families. Int Psychogeriatr. 2013;25(6):867\u201376.","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"1037_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-019-1406-6","volume":"20","author":"P Rapaport","year":"2020","unstructured":"Rapaport P, Burton A, Leverton M, et al. \u201cI just keep thinking that I don\u2019t want to rely on people.\u201d A qualitative study of how people living with dementia achieve and maintain independence at home: stakeholder perspectives. BMC Geriatr. 2020;20(1):5.","journal-title":"BMC Geriatr"},{"issue":"1","key":"1037_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/HRP.0000000000000352","volume":"31","author":"LG Richler","year":"2023","unstructured":"Richler LG, Shimizu M, Huang H, Kester R. Challenges of agitation in dementia: a plea for early discussion. Harv Rev Psychiatry. 2023;31(1):22\u20137.","journal-title":"Harv Rev Psychiatry"},{"issue":"8","key":"1037_CR43","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s40264-026-01670-w","volume":"49","author":"AP Porsteinsson","year":"2026","unstructured":"Porsteinsson AP, Chumki SR, Wang D, et al. Short-term and long-term safety analyses of brexpiprazole for agitation associated with dementia due to Alzheimer\u2019s disease: timing and duration of adverse events. Drug Saf. 2026;49(8):969\u201383.","journal-title":"Drug Saf"},{"issue":"5","key":"1037_CR44","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/sj.npp.1301492","volume":"33","author":"DV Jeste","year":"2008","unstructured":"Jeste DV, Blazer D, Casey D, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957\u201370.","journal-title":"Neuropsychopharmacology"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01037-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01037-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01037-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:56:53Z","timestamp":1792195013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01037-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":44,"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01037-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"23 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anton P. Porsteinsson has received personal fees from Acadia Pharmaceuticals, Athira, Axsome, Biogen, BMS, Cognitive Research Corp, Cognition Therapeutics, Eisai, IQVIA, Lundbeck, MapLight Therapeutics, Novartis, Novo Nordisk, Oligomerix, ONO Pharmaceuticals, Otsuka, WCG, WebMD, and Xenon; and his institution has received grants from Athira, Biogen, Cassava, Eisai, Eli Lilly, Genentech\/Roche, Vaccinex, NIA, NIMH, and DOD. He is a member of the Scientific Advisory Board of Alzheon, Athira, Cognition Therapeutics, and Oligomerix. Sanjeda R. Chumki, Anton M. Palma, and Zhen Zhang are full-time employees of Otsuka Pharmaceutical Development & Commercialization Inc. David Wang is a full-time employee of Lundbeck LLC. Pedro Such is a full-time employee of H. Lundbeck A\/S. C. Brendan Montano has received consulting fees from AbbVie, Acadia Pharmaceuticals, Alkermes, Arbor, Eisai, Neos, Novo Nordisk, Otsuka, Sunovion, Supernus, and Takeda, and has received payment\/honoraria from AbbVie, Arbor, Eisai, Otsuka, and Takeda.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required for this post hoc analysis. The original trials were approved by the appropriate institutional review boards and independent ethics committees and were conducted in accordance with the Helsinki Declaration of 1964 and its later amendments, the International Conference on Harmonisation Good Clinical Practice Guideline, and local regulatory requirements. Written or electronic informed consent was collected from participants and\/or their legal representatives.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}